Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration

Ranibizumab is a monoclonal antibody fragment that inhibits angiogenesis by inhibiting vascular endothelial growth factor A, used as a treatment for patients with wet aged-related macular degeneration (ARMD). Adverse effects from intravitreal Ranibizumab injections are well recognised. Macular hole...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Chandoshi, Mitra, Arijit, Kumar, N. Ajith, Elsherbiny, Samer, Lip, Peck Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763958/
https://www.ncbi.nlm.nih.gov/pubmed/26962382
http://dx.doi.org/10.2174/1874364101509010177
Descripción
Sumario:Ranibizumab is a monoclonal antibody fragment that inhibits angiogenesis by inhibiting vascular endothelial growth factor A, used as a treatment for patients with wet aged-related macular degeneration (ARMD). Adverse effects from intravitreal Ranibizumab injections are well recognised. Macular hole formation following Ranibizumab injection is a complication that has been recently reported in few case reports. We present a larger case series of five patients, who developed full thickness macular holes (FTMH) after intravitreal Ranibizumab injections for treatment of wet ARMD that we were aware of between 2009 and 2013.

Ejemplares similares